Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial
- DOI
- 10.1016/j.schres.2026.06.021
- Published
- 2026-10
- Container
- Schizophrenia Research
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.schres.2026.06.021,
title = {Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial},
author = {Julia M. Lappin and Patrick Bolton and Greg Smith and Xin-Yi Chua and Sarah Grattan and Katherine Samaras and Richard Day and Gordana Popovic and Maryanne O'Donnell and Sara Buten and Jakob Hansen and Scott Teasdale and Tang Wong and Emad El-Omar},
year = {2026},
journal = {Schizophrenia Research},
doi = {10.1016/j.schres.2026.06.021},
url = {https://doi.org/10.1016/j.schres.2026.06.021}
}RIS
TY - JOUR TI - Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial AU - Julia M. Lappin AU - Patrick Bolton AU - Greg Smith AU - Xin-Yi Chua AU - Sarah Grattan AU - Katherine Samaras AU - Richard Day AU - Gordana Popovic AU - Maryanne O'Donnell AU - Sara Buten AU - Jakob Hansen AU - Scott Teasdale AU - Tang Wong AU - Emad El-Omar PY - 2026 JO - Schizophrenia Research DO - 10.1016/j.schres.2026.06.021 UR - https://doi.org/10.1016/j.schres.2026.06.021 ER -
APA
Lappin, J. M., Bolton, P., Smith, G., Chua, X., Grattan, S., Samaras, K., Day, R., Popovic, G., O'Donnell, M., Buten, S., Hansen, J., Teasdale, S., Wong, T., & El-Omar, E. (2026). Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial. Schizophrenia Research. https://doi.org/10.1016/j.schres.2026.06.021
Source records
- crossref · retrieved 2026-09-26T15:37:58.022Z